The Challenge Inbeeo’s client, a specialty CNS company, is preparing for the launch of their novel product in a highly competitive indication. There had been extensive
The Challenge Inbeeo’s client was a small clinical stage pharmaceutical company that was developing a novel product to treat Idiopathic Pulmonary Fibrosis (IPF), who were
The Challenge Inbeeo’s client, a specialty pharmaceutical company, is commercializing a novel radiopharmaceutical for an orphan oncology indication in Japan. Pricing mechanisms in Japan presented
The Challenge Inbeeo’s client, the global leader in a specialty therapeutic area, is launching two products, both novel formulations of their existing oral treatments. At
The Challenge Inbeeo’s client, a global specialty company, was actively preparing for the launch of a Long-Acting Injectable form of their block-buster short-acting oral equivalent.
The Challenge In advance of an upcoming indication expansion for their advanced oncology product, Inbeeo’s client needed to understand the potential implications on HTA, pricing
